Genentech turns eye implant's focus to diabetes

With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already-approved drug to head off the leading cause of blindness in people with diabetes.
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME),
Genentech : FDA Approves Susvimo For Diabetic Macular Edema Treatment
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo
FDA approves ranibizumab for treating diabetic macular edema
The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the treatment of diabetic macular edema (DMO). According to the company,
FDA approves continuous delivery ranibizumab injection (Susvimo) for the treatment of diabetic macular edema
Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time.
FDA Approves Susvimo for Diabetic Macular Edema
Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a refillable ocular implant.
Hosted on MSN7d
Genentech’s Itovebi combo hits overall survival endpoint in HER2- breast cancer
The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...
pharmaphorum3d
Genentech extends small-molecule R&D with three platform deals
Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...
Genentech announces INAVO120 study met key secondary endpoint
Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study ...
Hosted on MSN5mon
Genentech lays off nearly 100 employees at South San Francisco office
(KRON) — Biotech firm Genentech is laying off nearly 100 employees at its South San Francisco headquarters, according to a WARN notice from the California Employment Development Department (EDD).
Wafaa Mamilli To Join Roche As Chief Digital Technology Officer
Wafaa Mamilli will join Roche as the company's new Chief Digital Technology Officer in February. This follows expansive roles ...
The Atlantic2mon
Fostering Healthcare Innovation Through Policy, Partnerships, and Collaborative Action
Since its founding in San Francisco in 1976, biotechnology pioneer Genentech has helped revolutionize the way doctors treat some of the world’s most complex health challenges, including the ...
San Francisco Bay Times2d
Joshua Nair of Genentech
Joshua Nair is a driven Principal Administrative Business Partner and Operations Manager at Genentech, with over a decade of ...
The Reporter5d
Lonza releases 2024 earnings report
Swiss Biotechnology firm Lonza, which purchased the Genentech facility in Vacaville last year, reported an income of 6.6 billion in Swiss francs (CHF) for the year 2024, which converts to about ...